Tissue Repair Platform

ECM Hydrogel

ECM-based materials strongly influence cell behavior, including the ability to redirect the default injury response of inflammation and scar tissue formation toward a response that mimics fetal development.

FDA approved ECM product, powder form FDA approved ECM product, solid form
Existing FDA-approved ECM products are in powder and solid form.
ECM Therapeutics Hydrogel
ECM Therapeutics Hydrogel. The hydrogel formulation affords broad expansion of therapeutic options.

Extracellular matrix based surgical mesh materials have been used clinically for decades. ECM Therapeutics’ innovative platform technology, the ECM hydrogel, is prepared from the whole ECM with tailorable properties customized to product performance specifications. ECMT’s extensive patent portfolio is backed by years of preclinical and clinical research with data supporting the safety and effectiveness of the extracellular matrix in an injectable, moldable formula.

Using proprietary decellularization technology, ECMT’s hydrogel provides a minimally invasive alternative to ECM mesh materials, expanding the clinical utility of ECM biomaterials including targeting hard-to-reach and irregularly shaped areas, coatings, and void filling without the need for surgical mesh placement. ECM hydrogels retain the structural and biologic environment of native tissue while providing an inductive template for tissue remodeling to resolve disease and injury.

Pipeline

ECM Hydrogel Product Pipeline

CompoundDisease AreaStage
ECMT-100Fistula RepairPhase 1
ECMT-200GI StricturePre-Clinical
ECMT-300Dermal FillerPre-Clinical

ECM Therapeutics’ proprietary cGMP large-scale manufacturing capabilities include producing sterile ECM hydrogels, colloids, coatings, oral solutions, injectables and creams. ECM Hydrogel can also be loaded and used as a carrier.